Search
for
Sort by
Research 541–570 of 774
- 689 Cell-type-specific nascent transcriptomics through PRECISE-seq reveal molecular principles of tissue dynamics
- The Frontal Fibrosing Alopecia Treatment Dilemma
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
- Treatment of pediatric alopecia areata: A systematic review
- Association of atopic dermatitis with autoimmune diseases: A bidirectional and multivariable two-sample mendelian randomization study
- A clinician’s guide to pediatric and adolescent alopecia areata treatments
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
- Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
- Hair
- 83 Transcriptomic meta-analysis and deconvolution approaches unveil cellular dynamics in scarring and non-scarring primary lymphocytic alopecias
- Hair Loss in an 11-year-old
- Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- A novel therapeutic paradigm for patients with extensive alopecia areata